ViiV Healthcare has announced 109 projects from 26 countries that have received funding from its £3m Global HIV and Covid-19 Emergency Response Fund, which was launched at the end of April.

The fund involves two major streams – research grants and community grants. It aims to support projects researching the medical impact of Covid-19 on people living with HIV, as well as help necessary local initiatives and organisations that are struggling to support the HIV community in the pandemic.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company’s head of external affairs and communications Stephen Rea said: “The overwhelming response from research and community-based organisations to our Global HIV and COVID-19 Emergency Response Fund underlines the significant burden felt by people living with HIV during the pandemic. 

“Very understandably, people living with HIV and their physicians have mounting questions about the risks COVID-19 poses, and so we have elected to use our Research grants to support those studies seeking to find answers.

“It’s our hope that our Community grants will help mitigate some of the disruptions to health services and supplies, which the WHO and UNAIDS have estimated could lead to more than half a million additional AIDS-related deaths.” 

One of the recipients of research grant funding is Harvard Medical School professor of medicine and one of the leader investigators of HIV REPRIEVE study Dr Steven Grinspoon.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

He stated: “With support from ViiV Healthcare, we will investigate an innovative approach, using proteomics, to test whether the introduction of statins will mitigate the severity of Covid-19 in people living with HIV, and whether such effects will lead to an improved response to Covid-related inflammation, immune activation, and complications in the heart and lungs.

“Through our research, we hope to provide much needed information about COVID-19, the impact of HIV on the body’s immune response to Covid-19, and the possible protective effects of statins that will be important for people living with HIV as well as the general population.”